EnginZyme raises €21 million in Series B to accelerate the commercialisation of its cell-free biomanufacturing technology
Summary
STOCKHOLM, Sweden, December 19, 2022 -- EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced today that it had raised 21 million in a Series B financing round. Its technology platform utilises natures catalysts, enzymes, combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution. By replacing traditional fossil-based manufacturing with its patented cell-free technology platform, the company seeks to accelerate the shift toward more sustainable manufacturing of the products that modern society relies on.EnginZyme, which is recognised as a Technology Pioneer by the World Economic Forum, will use the Series B funds to execute its plans for large-scale global commercialisation and build new features of its proprietary technology platform to enhance performance and facilitate scaling in current and new markets.This fundraising marks a pivotal moment for EnginZyme," said Dr Karim Engelmark Cassimjee, CEO and co-founder of EnginZyme. We look forward to supporting the company alongside our fellow co-investors.Founded in Sweden in 2014, EnginZyme wants to play a key role in tackling climate change by enabling green chemistry for every industry. By replacing traditional fossil-based manufacturing with the patented cell-free technology platform, EnginZyme seeks to accelerate the shift toward the sustainable biomanufacturing of products that modern society relies on.EnginZyme is recognised as a Technology Pioneer by the World Economic Forum, named a Global Cleantech 100 company, and is backed by an international syndicate of investors: Sofinnova Partners, Industrifonden, SEB GreenTech VC, Almi Invest GreenTech, Navigare Ventures and Bunge Ventures.
Funding
Review available funding amount, funding date, investors, and linked company information related to EnginZyme raises €21 million in Series B to accelerate the commercialisation of its cell-free biomanufacturing technology in the interactive ISVWorld profile.